

Amendments to the Claims:

Please amend the pending claims as follows:

Listing of Claims

B2 1. (Currently amended): A recombinant avian herpesvirus comprising a ~~herpes-virus~~ herpesvirus of turkeys unique long and repeat viral genome region that corresponds to nucleotide positions 1 to 136,040 of GenBank accession No. AF291866 and a Marek's disease virus unique short viral genome region that corresponds to nucleotide positions 66 to 11,221 of GenBank accession No. L22174 wherein at least one foreign DNA sequence is inserted within a US2 gene of the unique short region of the recombinant avian herpesvirus and is capable of being expressed in a host cell.

2. (Original): The recombinant avian herpesvirus of claim 1 wherein the foreign DNA sequence is selected from the group consisting of: a Newcastle disease virus fusion gene, an infectious laryngotracheitis virus glycoprotein D gene, or an infectious laryngotracheitis glycoprotein I gene.

3. (Original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the Newcastle disease virus fusion gene.

B3 4. (Previously amended): The recombinant avian herpesvirus of claim 3 designated NAHV/NDV 295-93 (ATCC Accession number PTA-3453).

5. (Original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein D gene.

6. (Original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein I gene.

7. (Original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequences are the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene.

B4 8. (Previously amended) The recombinant avian herpesvirus of claim 7 designated NAHV/ILT 295-149 (ATCC Accession number PTA-3452).

9. (Original): The recombinant avian herpesvirus of claim 2 wherein the foreign DNA sequences are the Newcastle disease virus fusion gene, the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene.

---

B5 10. (Previously amended): The recombinant avian herpesvirus designated NAHV 295-01 (ATCC Accession number PTA-3451).

---

11. (Original): A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 3 and a suitable carrier.

12. (Original): A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 4 and a suitable carrier.

13. (Original): A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 7 and a suitable carrier.

14. (Original): A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 8 and a suitable carrier.

---

B6 15. (Currently amended): A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 10 and a suitable carrier.

---

16. (Original): A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 9 and a suitable carrier.

---

B7 17. (Previously amended): A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising, as a mixture, an effective immunizing amount of a first recombinant avian herpesvirus, designated NAHV/ILT 295-149 (ATCC Accession number PTA-3452), an effective immunizing amount of a second

recombinant avian herpesvirus, designated NAHV/NDV 295-93 (ATCC Accession number PTA-3453), and a suitable carrier.

B7

18. (Original): A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 11.

19. (Original): A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 12.

20. (Original): A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of claim 13.

21. (Original): A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of claim 14.

22. (Currently amended): A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of vaccine of claim 15.

B8

23. (Original): A method of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 16.

24. (Original): The vaccine as in claim 11 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

25. (Original): The vaccine as in claim 13 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

26. (Original): The vaccine as in claim 15 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

27. (Original): The vaccine as in claim 16 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

28. (Original): The method of claim 18, wherein the vaccine is administered by injection.

29. (Original): The method of claim 20, wherein the vaccine is administered by injection.

30. (Original): The method of claim 22, wherein the vaccine is administered by injection.

31. (Original): The method of claim 23, wherein the vaccine is administered by injection.

32. (Original): The method of claim 18, wherein the vaccine is administered intraocularly.

33. (Original): The method of claim 20, wherein the vaccine is administered intraocularly.

34. (Original): The method of claim 22, wherein the vaccine is administered intraocularly.

35. (Original): The method of claim 23, wherein the vaccine is administered intraocularly.

36. (Original): The method of claim 18, wherein the vaccine is administered orally.

37. (Original): The method of claim 20, wherein the vaccine is administered orally.

38. (Original): The method of claim 22, wherein the vaccine is administered orally.

39. (Original): The method of claim 23, wherein the vaccine is administered orally.

40. (New): A recombinant avian herpesvirus comprising a herpesvirus of turkeys unique long and repeat viral genome region that corresponds to nucleotide positions 1 to 136,040 of GenBank accession No. AF291866 and a Marek's disease virus unique short viral genome region that corresponds to nucleotide positions 66 to 11,221 of GenBank accession No. L22174 wherein at least

B9

one foreign DNA sequence is inserted within a non-essential site of the recombinant avian herpesvirus viral genome and is capable of being expressed in a host cell.

41. (New): A recombinant avian herpesvirus comprising a herpesvirus of turkeys unique long and repeat viral genome region that corresponds to nucleotide positions 1 to 136,040 of GenBank accession No. AF291866 and a Marek's disease virus unique short viral genome region that corresponds to nucleotide positions 66 to 11,221 of GenBank accession No. L22174.

42. (New): A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of claim 41 and a suitable carrier.

43. (New): A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of claim 42.

44. (New): The vaccine as in claim 42 wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents.

45. (New): The method of claim 43, wherein the vaccine is administered by injection.

B9 46. (New): The method of claim 43, wherein the vaccine is administered intraocularly.

47. (New): The method of claim 43, wherein the vaccine is administered orally.

---